Time To Efficacy and Onset Of Action Of Linezolid
Sponsor
Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00147511
Collaborator
(none)
118
24
Study Details
Study Description
Brief Summary
To assess the onset of action of linezolid
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
118 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections
Study Start Date
:
Jun 1, 2003
Actual Study Completion Date
:
Jun 1, 2005
Outcome Measures
Primary Outcome Measures
- Time to defervescence []
Secondary Outcome Measures
- Reduction of CRP levels Reduction of leucocyte count []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
suspected grampositive infection
-
fever > 38 C
Exclusion Criteria:
- Infections to be treated successfully by surgical procedures
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00147511
Other Study ID Numbers:
- OXAA-0026-162
First Posted:
Sep 7, 2005
Last Update Posted:
May 10, 2011
Last Verified:
May 1, 2011
Additional relevant MeSH terms: